US pharma co denied patent on hepatitis C combo therapy
NEW DELHI: The Indian Patent Office has refused to grant a patent to US pharmaceutical firm AbbVie on its Hepatitis C combination therapy glecaprevir/pibrentasvir, marketed globally as Mavyret. The combination therapy is considered a key treatment for Hepatitis C, and the availability of affordable generic versions remains critical for widening patient access. “The order demonstrates…